FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912622074> ?p ?o ?g. }

• W2912622074 endingPage "31" @default.
• W2912622074 startingPage "1" @default.
• W2912622074 abstract "The rise in non-AIDS defining cancers (NADCs) is emerging as a leading cause of death for HIV and cancer patients. To address this, current literature and guidelines suggest the continuation of antiretroviral therapy (ART) with oral oncolytic agents to prevent adverse complications associated with HIV disease progression. However, such an approach has the potential for drug-drug interactions and adverse events for patients on such therapy. Further, recommendations on how to adjust these medications, when used concomitantly, are limited. As such, our purpose is to evaluate existing literature through such means as drug databases (e.g. Micromedex, Lexi-Comp, etc.) and package inserts along with PubMed/Medline, Embase, and Google Scholar databases to develop a reference tool for providers to utilize when there is a decision to treat a patient with ART and oral oncolytic agents concurrently. Our findings suggest that there are many drug interactions that should be taken into consideration with dual therapy. Metabolism is a key determinant of dose adjustment, and many oncolytic agents and ART agents must have their dose adjusted as such. Most notably, several tyrosine kinase inhibitors require dose increases when used with non-nucleoside reverse transcriptase inhibitors (NNRTIs) but must be decreased when used concomitantly with protease inhibitors (PIs) and cobicistat. Further findings suggest that certain agents should not be used together, which include, but are not limited to, such combinations as bosutinib with NNRTIs, cobicistat, or PIs; idelalisib with maraviroc or PIs; neratinib with NNRTIs, cobicistat, or PIs; and venetoclax with NNRTIs. Overall, the most prominent oncolytic drug interactions were discovered when such agents were used concomitantly with PIs, cobicistat-boosted elvitegravir, or NNRTIs. Future studies are necessary to further evaluate the use of these agents together in disease therapy to generate absolute evidence of such findings. However, from the studies evaluated, much evidence exists to suggest that concomitant therapy is not without drug interactions. As such, clinical decisions regarding concomitant therapy should be evaluated in which the risk and benefit of dual therapy are assessed. Dose adjustments must be made accordingly and in consultation with both HIV and oncology clinicians and pharmacists to reduce the risk for adverse outcomes and disease progression for those with cancer and HIV/AIDS." @default.
• W2912622074 created "2019-02-21" @default.
• W2912622074 creator A5037434875 @default.
• W2912622074 creator A5042302964 @default.
• W2912622074 creator A5045392095 @default.
• W2912622074 creator A5057833339 @default.
• W2912622074 date "2019-02-13" @default.
• W2912622074 modified "2023-10-11" @default.
• W2912622074 title "Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use" @default.
• W2912622074 cites W1061111608 @default.
• W2912622074 cites W114049227 @default.
• W2912622074 cites W1249055141 @default.
• W2912622074 cites W1512207708 @default.
• W2912622074 cites W1594192081 @default.
• W2912622074 cites W1903247254 @default.
• W2912622074 cites W1939210775 @default.
• W2912622074 cites W1952424916 @default.
• W2912622074 cites W1970807670 @default.
• W2912622074 cites W1971774948 @default.
• W2912622074 cites W1987045819 @default.
• W2912622074 cites W1989798818 @default.
• W2912622074 cites W1997264225 @default.
• W2912622074 cites W1997567636 @default.
• W2912622074 cites W1998368976 @default.
• W2912622074 cites W1999742630 @default.
• W2912622074 cites W2006395976 @default.
• W2912622074 cites W2007705311 @default.
• W2912622074 cites W2012132529 @default.
• W2912622074 cites W2021218460 @default.
• W2912622074 cites W2024132020 @default.
• W2912622074 cites W2029309243 @default.
• W2912622074 cites W2035060068 @default.
• W2912622074 cites W2042239874 @default.
• W2912622074 cites W2048865850 @default.
• W2912622074 cites W2076178766 @default.
• W2912622074 cites W2086291342 @default.
• W2912622074 cites W2088540000 @default.
• W2912622074 cites W2094969552 @default.
• W2912622074 cites W2104830962 @default.
• W2912622074 cites W2108753267 @default.
• W2912622074 cites W2111464471 @default.
• W2912622074 cites W2117989534 @default.
• W2912622074 cites W2121545342 @default.
• W2912622074 cites W2122406360 @default.
• W2912622074 cites W2122994164 @default.
• W2912622074 cites W2125129553 @default.
• W2912622074 cites W2134575967 @default.
• W2912622074 cites W2135121954 @default.
• W2912622074 cites W2142046222 @default.
• W2912622074 cites W2146816088 @default.
• W2912622074 cites W2148320771 @default.
• W2912622074 cites W2160020988 @default.
• W2912622074 cites W2163974352 @default.
• W2912622074 cites W2274638546 @default.
• W2912622074 cites W2297120379 @default.
• W2912622074 cites W2401259207 @default.
• W2912622074 cites W2401440115 @default.
• W2912622074 cites W2549759675 @default.
• W2912622074 cites W2562572403 @default.
• W2912622074 cites W2581819333 @default.
• W2912622074 cites W2741447616 @default.
• W2912622074 cites W2742938524 @default.
• W2912622074 cites W37559546 @default.
• W2912622074 doi "https://doi.org/10.7573/dic.212550" @default.
• W2912622074 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6383448" @default.
• W2912622074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30815023" @default.
• W2912622074 hasPublicationYear "2019" @default.
• W2912622074 type Work @default.
• W2912622074 sameAs 2912622074 @default.
• W2912622074 citedByCount "13" @default.
• W2912622074 countsByYear W29126220742019 @default.
• W2912622074 countsByYear W29126220742020 @default.
• W2912622074 countsByYear W29126220742021 @default.
• W2912622074 countsByYear W29126220742022 @default.
• W2912622074 crossrefType "journal-article" @default.
• W2912622074 hasAuthorship W2912622074A5037434875 @default.
• W2912622074 hasAuthorship W2912622074A5042302964 @default.
• W2912622074 hasAuthorship W2912622074A5045392095 @default.
• W2912622074 hasAuthorship W2912622074A5057833339 @default.
• W2912622074 hasBestOaLocation W29126220741 @default.
• W2912622074 hasConcept C121608353 @default.
• W2912622074 hasConcept C126322002 @default.
• W2912622074 hasConcept C142462285 @default.
• W2912622074 hasConcept C143998085 @default.
• W2912622074 hasConcept C159047783 @default.
• W2912622074 hasConcept C177713679 @default.
• W2912622074 hasConcept C197934379 @default.
• W2912622074 hasConcept C2777329042 @default.
• W2912622074 hasConcept C2777938653 @default.
• W2912622074 hasConcept C2778461978 @default.
• W2912622074 hasConcept C2778723075 @default.
• W2912622074 hasConcept C2779786085 @default.
• W2912622074 hasConcept C2779878957 @default.
• W2912622074 hasConcept C2780524789 @default.
• W2912622074 hasConcept C2993143319 @default.
• W2912622074 hasConcept C3013748606 @default.
• W2912622074 hasConcept C530470458 @default.
• W2912622074 hasConcept C71924100 @default.

• next